*Madam ---* Immunotherapy has improved non-small cell lung cancer (NSCLC) survival \[[@bib1]\]. The COVID-19 pandemic has led NHS England to suggest stopping maintenance pemetrexed and using pembrolizumab monotherapy in patients with a tumour proportion score (TPS) \< 50% \[[@bib2]\].

Before immunotherapy, pemetrexed improved median overall survival (mOS) by 2.9 months \[[@bib3],[@bib4]\]. In KEYNOTE-189, adding pembrolizumab improved mOS across all TPS subgroups \[[@bib5]\]. However, the mOS in the TPS \<1% subgroup (17.2 months) was similar to pemetrexed maintenance studies. Given the higher rate of severe adverse events (71.9% versus 66.8%) and immune-related adverse events (10.9% versus 4.5%) with immunotherapy \[[@bib5]\], pemetrexed monotherapy may be preferable in TPS \< 1% patients.

KEYNOTE-042 randomised untreated metastatic NSCLC patients to pembrolizumab monotherapy or chemotherapy, showing a mOS of 20, 17.7 and 16.7 months in TPS groups \>50%, \>20%, \>1%, respectively \[[@bib6]\]. This was inferior to the mOS observed in KEYNOTE-189 (TPS 1--49%: 21.8 months; TPS \< 1%: 17.2 months) \[[@bib5]\]. KEYNOTE-407 assessed triple therapy in metastatic squamous NSCLC and showed a superior progression-free survival of 7.2 months (TPS 1--49% group) and 6.3 months (TPS \< 1% group) \[[@bib7]\] compared with the progression-free survival of 6.2 months (TPS \> 20% group) and 5.4 months (TPS \> 1% group) in KEYNOTE-042 \[[@bib6]\]. Critically, in KEYNOTE-042, up to 72% of the lower TPS subgroups included patients with a TPS \>50%, probably inflating the mOS observed \[[@bib6]\].

The survival advantages of triple therapy come at a cost of higher rates of adverse events (71.9% versus 18%), particularly myelosuppression (15% versus \<2%) \[[@bib5],[@bib6]\]. Immune-related adverse events can be equally challenging to manage and may present with features that overlap with COVID-19 infection. Using immunosuppression was initially thought to be detrimental with COVID-19 \[[@bib8]\], but the awaited RECOVERY trial publication may clarify this issue \[[@bib9]\].

There is limited evidence for the efficacy of pembrolizumab monotherapy in TPS 0--49%. The European Medicines Agency has declined licensing for this indication \[[@bib10]\]. Despite interim guidance, there is an efficacy and safety trade-off that must be acknowledged.
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